5.I4.2 — Pet

Items

• 61333

  Lung ventilation study using Galligas and lung perfusion study using gallium-...
• 61336

  Cerebral study, with PET, if the service is performed because the service to ...
• 61341

  Bone study – whole body with PET, with delayed imaging when undertaken, if th...
• 61523

  Whole body FDG PET study, performed for evaluation of a solitary pulmonary no...
• 61524

  Whole body FDG PET study, performed for the staging of locally advanced (Stag...
• 61525

  Whole body FDG PET study, performed for the evaluation of suspected metastati...
• 61527

  Whole body study using PET, if the service is performed because the services ...
• 61528

  Whole body PSMA PET study, performed for the assessment of suitability for Lu...
• 61529

  Whole body FDG PET study, performed for the staging of proven non-small cell ...
• 61538

  FDG PET study of the brain for evaluation of suspected residual or recurrent ...
• 61541

  Whole body FDG PET study, following initial therapy, for the evaluation of su...
• 61553

  Whole body FDG PET study, following initial therapy, performed for the evalua...
• 61559

  FDG PET study of the brain, performed for the evaluation of refractory epilep...
• 61560

  FDG PET study of the brain, performed for the diagnosis of Alzheimer’s diseas...
• 61563

  Whole body prostate-specific membrane antigen PET study performed for the ini...
• 61564

  Whole body prostate-specific membrane antigen PET study performed for the res...
• 61565

  Whole body FDG PET study, following initial therapy, performed for the evalua...
• 61571

  Whole body FDG PET study, for the further primary staging of patients with hi...
• 61575

  Whole body FDG PET study, for the further staging of patients with confirmed ...
• 61577

  Whole body FDG PET study, performed for the staging of proven oesophageal or ...
• 61598

  Whole body FDG PET study performed for the staging of biopsy-proven newly dia...
• 61604

  Whole body FDG PET study performed for the evaluation of patients with suspec...
• 61610

  Whole body FDG PET study performed for the evaluation of metastatic squamous ...
• 61612

  Whole body FDG PET study for the initial staging of cancer, for a patient who...
• 61614

  Whole body FDG PET study, following initial therapy, performed for the evalua...
• 61620

  Whole body FDG PET study for the initial staging of newly diagnosed or previo...
• 61622

  Whole body FDG PET study to assess response to first line therapy either duri...
• 61628

  Whole body FDG PET study for restaging following confirmation of recurrence o...
• 61632

  Whole body FDG PET study to assess response to second-line chemotherapy if ha...
• 61640

  Whole body FDG PET study for initial staging of patients with biopsy-proven b...
• 61644

  Single rest myocardial perfusion study for the assessment of the extent and s...
• 61646

  Whole body FDG PET study for the evaluation of patients with suspected residu...
• 61647

  Whole body 68Ga DOTA peptide PET study, if:(a) a gastro entero pancreatic neu...